Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a coc… Read more
Artelo Biosciences Inc (ARTL) - Net Assets
Latest net assets as of December 2025: $-1.27 Million USD
Based on the latest financial reports, Artelo Biosciences Inc (ARTL) has net assets worth $-1.27 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.80 Million) and total liabilities ($4.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.27 Million |
| % of Total Assets | -45.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | -110.56% |
| 10-Year Change | N/A |
| Growth Volatility | 113.15 |
Artelo Biosciences Inc - Net Assets Trend (2014–2025)
This chart illustrates how Artelo Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Artelo Biosciences Inc (2014–2025)
The table below shows the annual net assets of Artelo Biosciences Inc from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-1.27 Million | -144.52% |
| 2024-12-31 | $2.86 Million | -75.69% |
| 2023-12-31 | $11.75 Million | -39.43% |
| 2022-12-31 | $19.40 Million | +61.13% |
| 2021-12-31 | $12.04 Million | +210.79% |
| 2020-12-31 | $3.87 Million | -29.05% |
| 2019-12-31 | $5.46 Million | +4146.12% |
| 2018-12-31 | $-134.97K | -124.77% |
| 2017-12-31 | $544.84K | +4048.09% |
| 2016-12-31 | $-13.80K | -190.26% |
| 2015-12-31 | $15.29K | -48.10% |
| 2014-12-31 | $29.46K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Artelo Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6299973100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | % |
| Other Comprehensive Income | $-272.00K | % |
| Other Components | $62.01 Million | % |
| Total Equity | $-1.27 Million | 100.00% |
Artelo Biosciences Inc Competitors by Market Cap
The table below lists competitors of Artelo Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MK Trend Co. Ltd.
KO:069640
|
$3.51 Million |
|
ODIGMA CONSULTANCY SOLUTIONS LTD
NSE:ODIGMA
|
$3.52 Million |
|
Arshiya Limited
NSE:ARSHIYA
|
$3.52 Million |
|
Nepa AB
ST:NEPA
|
$3.52 Million |
|
Cannabis Sativa Inc
OTCQB:CBDS
|
$3.51 Million |
|
Kakatiya Cement Sugar & Industries Limited
NSE:KAKATCEM
|
$3.51 Million |
|
Great Atlantic Resources Corp
V:GR
|
$3.51 Million |
|
Complii Fintech Solutions Ltd
AU:CF1
|
$3.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Artelo Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,857,000 to -1,272,000, a change of -4,129,000 (-144.5%).
- Net loss of 12,879,000 reduced equity.
- New share issuances of 6,151,000 increased equity.
- Other comprehensive income decreased equity by 70,000.
- Other factors increased equity by 2,669,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.88 Million | -1012.5% |
| Share Issuances | $6.15 Million | +483.57% |
| Other Comprehensive Income | $-70.00K | -5.5% |
| Other Changes | $2.67 Million | +209.83% |
| Total Change | $- | -144.52% |
Book Value vs Market Value Analysis
This analysis compares Artelo Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $3.45 | $4.85 | x |
| 2015-12-31 | $1.44 | $4.85 | x |
| 2016-12-31 | $-1.30 | $4.85 | x |
| 2017-12-31 | $44.92 | $4.85 | x |
| 2018-12-31 | $-9.51 | $4.85 | x |
| 2019-12-31 | $226.25 | $4.85 | x |
| 2020-12-31 | $94.06 | $4.85 | x |
| 2021-12-31 | $58.03 | $4.85 | x |
| 2022-12-31 | $41.09 | $4.85 | x |
| 2023-12-31 | $3.97 | $4.85 | x |
| 2024-12-31 | $0.89 | $4.85 | x |
| 2025-12-31 | $-1.24 | $4.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Artelo Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-78.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -103.65% | 0.00% | 0.00x | 1.00x | $-16.74K |
| 2015 | -99.68% | 0.00% | 0.00x | 1.11x | $-16.77K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.31K |
| 2017 | -43.11% | 0.00% | 0.00x | 1.05x | $-289.37K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.33 Million |
| 2019 | -39.77% | 0.00% | 0.00x | 1.19x | $-2.72 Million |
| 2020 | -120.14% | 0.00% | 0.00x | 1.13x | $-5.04 Million |
| 2021 | -61.76% | 0.00% | 0.00x | 1.05x | $-8.64 Million |
| 2022 | -51.97% | 0.00% | 0.00x | 1.05x | $-12.02 Million |
| 2023 | -79.04% | 0.00% | 0.00x | 1.11x | $-10.46 Million |
| 2024 | -343.93% | 0.00% | 0.00x | 1.64x | $-10.11 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.75 Million |
Industry Comparison
This section compares Artelo Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Artelo Biosciences Inc (ARTL) | $-1.27 Million | -103.65% | N/A | $3.51 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |